

# Synthesis of a 2-Hydrazinyl-1,6-dihydropyrimidine Derivative

A. K. Shiryayev<sup>a,\*</sup>, E. A. Lashmanova<sup>a</sup>, and A. V. Trofimova<sup>a</sup>

<sup>a</sup> Samara State Technical University, ul. Molodogvardeiskaya 244, Samara, 443100 Russia

\*e-mail: shiryayev.ak@samgtu.ru

Received November 7, 2018; revised November 11, 2018; accepted December 16, 2018

**Abstract**—Ethyl 4-methyl-6-phenyl-2-[2-(propan-2-ylidene)hydrazinyl]-1,6-dihydropyrimidine-5-carboxylate has been synthesized from ethyl 2-(ethoxymethylidene)-7-methyl-3-oxo-5-phenyl-3,5-dihydro-2*H*-[1,3]thiazolo[3,2-*a*]pyrimidine-6-carboxylate.

**Keywords:** pyrimidine, thiazolopyrimidine, nucleophilic substitution, hydrazine derivatives, nitrosation, ethoxymethylidene derivatives.


**DOI:** 10.1134/S1070428019030102

Biginelli synthesis of pyrimidines [1] is attractive due to simplicity of the experimental procedure and accessibility of initial reagents [2–6]. On the other hand, neither guanidine nor aminoguanidine can be involved in the Biginelli reaction, so that the corresponding 2-amino- and 2-hydrazinyl-1,6-dihydropyrimidines were synthesized by condensation of protected guanidine with subsequent deprotection [7] or via substitution of an appropriate nucleofugal group on C<sup>2</sup> of the dihydropyrimidine ring by hydrazinyl or amino group [7–10]. A series of 2-amino-1,6-dihydropyrimidines were obtained by substitution of the pyrazolyl group in *N*<sup>1</sup>-Boc-2-(1*H*-pyrazol-1-yl)-1,6-dihydropyrimidines by an ammonia or primary amine residue [7, 8]. The reaction of more accessible 2-(ben-


zylsulfanyl)-1,6-dihydropyrimidine **1** [9] or ethyl 2-(1,6-dihydropyrimidin-2-ylsulfanyl)acetates **2** [10] with hydrazine hydrate afforded 2-hydrazinyl-1,6-dihydropyrimidines **3** and **4**, respectively (Scheme 1). It should be noted that 2-hydrazinylpyrimidines **4** were converted to 2-(1*H*-pyrazol-1-yl)pyrimidines [10] which were used to synthesize 2-amino-1,6-dihydropyrimidines [7, 8].

We previously found that ethyl 2-(1,6-dihydropyrimidin-2-ylsulfanyl)acetates **2** as free bases are unstable in solution and that they readily undergo intramolecular cyclization to [1,3]thiazolo[3,2-*a*]pyrimidin-3(2*H*)-ones [11]. The latter were expected to give rise to 2-hydrazinyl-1,6-dihydropyrimidines in reaction with hydrazine hydrate. However, the reaction of

Scheme 1.



Scheme 2.



thiazolopyrimidine **5a** with hydrazine hydrate led to the formation of known 1,2,3,4-tetrahydropyrimidine-2-one **6** (Scheme 2) which was also synthesized by reaction of hydrazine hydrate with 2-hydroxyimino derivative **5b** prepared by nitrosation of **5a** [12]. In order to obtain 2-substituted 1,6-dihydropyrimidines, we have synthesized 2-(ethoxymethylidene)[1,3]thiazolo[3,2-*a*]pyrimidine **5c** by treatment of **5a** with triethyl orthoformate in acetic anhydride. The reaction of **5c** with hydrazine hydrate afforded 2-hydrazinyl-1,6-dihydropyrimidine which was isolated as acetone hydrazone **7**. The ethoxy group in 5-(ethoxymethylidene)-2-sulfanylidene-1,3-thiazolidin-4-one can be replaced by hydrazine residue [13], while the thiazolidine ring in [1,3]thiazolo[3,2-*a*]pyrimidine is readily opened by the action of, e.g., piperidine [14]. Hydrazine is a binucleophile which is likely to replace the ethoxy group in **5c** in the initial stage and thus favors further transformations leading to 2-hydrazinyl-1,6-dihydropyrimidine derivative. The described reaction opens a new synthetic route to 2-hydrazinyl-1,6-dihydropyrimidines.

#### EXPERIMENTAL

The IR spectra were recorded on a Shimadzu IR Affinity-1 spectrometer equipped with an ATR acces-

sory. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were measured on a Jeol JNM ECX spectrometer at 400 and 100 MHz, respectively, using  $\text{CDCl}_3$  as solvent and reference. The elemental analyses were obtained on a EuroVector EA 3000 automated CHNS analyzer. The melting points were measured in capillaries on an OptiMelt SRS MPA100 apparatus. Thin-layer chromatography was performed on Silufol UV-254 plates; spots were visualized by treatment with iodine vapor. [1,3]Thiazolo[3,2-*a*]pyrimidines **5a** and **5b** were synthesized according to the procedures described in [12, 15].

**Ethyl 2-(ethoxymethylidene)-7-methyl-5-phenyl-3,5-dihydro-2H-[1,3]thiazolo[3,2-*a*]pyrimidine-6-carboxylate (**5c**).** A mixture of 1.00 g (3.16 mmol) of thiazolopyrimidine **5a**, 1.65 mL (9.91 mmol) of triethyl orthoformate, and 10 mL of acetic anhydride was refluxed for 5 h. Excess acetic anhydride and liberated acetic acid were distilled off on an oil bath under reduced pressure (water-jet pump), and the residue was recrystallized from ethanol. Yield 0.40 g (34%), claret red crystals, mp 154–155°C. IR spectrum,  $\nu$ ,  $\text{cm}^{-1}$ : 3032 w ( $\text{C-H}_{\text{arom}}$ ), 2978 w and 2928 w ( $\text{C-H}_{\text{aliph}}$ ), 1703 s ( $\text{C=O}$ ), 1632 s ( $\text{C=N}$ ), 1607 s ( $\text{C=C}$ ), 1533 s ( $\text{C=C}_{\text{arom}}$ ), 1304 s ( $\text{C-N}$ ), 1217 s ( $\text{C-O}$ ), 1123 s ( $\text{C-O}$ ), 1070 s ( $\text{C-O}$ ), 1013 s ( $\text{C-O}$ ), 733 s ( $\delta\text{C-H}_{\text{arom}}$ ), 694 s ( $\delta\text{C-H}_{\text{arom}}$ ).  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm: 1.17 t (3H,

CH<sub>3</sub>,  $J = 7.1$  Hz), 1.34 t (3H, CH<sub>3</sub>,  $J = 7.4$  Hz), 2.46 s (3H, CH<sub>3</sub>), 4.06–4.14 m (4H, CH<sub>2</sub>O), 6.1 s (1H, CH), 7.25–7.35 m (6H, Ph, OCH=). <sup>13</sup>C NMR spectrum,  $\delta_C$ , ppm: 14.2 (CH<sub>3</sub>), 15.4 (CH<sub>3</sub>), 22.9 (CH<sub>3</sub>), 55.1 (CH), 60.4 (CH<sub>2</sub>O), 72.2 (CH<sub>2</sub>O), 101.4 (C<sup>2</sup>), 108 (C<sup>6</sup>); 127.9 (CH), 128.5 (CH), 128.6 (CH), 140.7 (Ph); 153.0 (C<sup>7</sup>), 153.3 (CHOEt), 157.5 (C<sup>8a</sup>) 165.3 (C<sup>3</sup>), 165.7 (6-C=O). Found, %: C 61.38; H 5.49; N 7.40; S 8.53. C<sub>19</sub>H<sub>20</sub>N<sub>2</sub>O<sub>4</sub>S. Calculated, %: C 61.27; H 5.41; N 7.52; S 8.61.

**Ethyl 6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (6).** Hydrazine hydrate, 0.4 mL (8 mmol), was added with stirring to a solution of 190 mg (0.6 mmol) of thiazolopyrimidine **5a** or 210 mg (0.6 mmol) of **5b** in 5 mL of ethanol. The mixture was refluxed for 3 h and cooled, and the precipitate was filtered off and washed with ethanol. Yield 110 mg (70%) from **5a** or 96 mg (61%) from **5b**, white crystals, mp 201–202°C; published data [16]: mp 202–204°C. IR spectrum,  $\nu$ , cm<sup>-1</sup>: 3246 s (N–H), 3117 s (N–H), 2980 m (C–H), 2930 m (C–H), 1726 s (C=O), 1701 s (C=O), 1649 s (C=C), 1223 s (C–O), 1092 s (C–O), 758 m ( $\delta$ C–H<sub>arom</sub>), 698 m ( $\delta$ C–H<sub>arom</sub>). <sup>1</sup>H NMR spectrum,  $\delta$ , ppm: 1.15 t (3H, CH<sub>3</sub>,  $J = 7.1$  Hz), 2.34 s (3H, CH<sub>3</sub>), 4.01–4.11 m (2H, CH<sub>2</sub>O), 5.40 s (1H, CH), 5.61 s (1H, NH), 7.20–7.35 m (5H, Ph), 7.83 s (1H, NH). <sup>13</sup>C NMR spectrum,  $\delta_C$ , ppm: 12.8 (CH<sub>3</sub>), 17.4 (CH<sub>3</sub>), 54.4 (CH), 58.7 (CH<sub>2</sub>O), 100.1 (C<sup>5</sup>); 125.2 (CH), 126.6 (CH), 127.4 (CH), 142.3 (Ph); 144.8 (C<sup>6</sup>), 151.7 (C<sup>2</sup>), 164.2 (5-C=O). Found, %: C 64.72; H 6.09; N 10.90. Calculated, %: C 64.60; H 6.20; N 10.76. C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>.

**Ethyl 4-methyl-6-phenyl-2-[2-(propan-2-ylidene)hydrazinyl]-1,6-dihydropyrimidine-5-carboxylate (7).** A mixture of 180 mg (0.48 mmol) of thiazolopyrimidine **5c**, 4 mL of propan-2-ol, and 0.3 mL (6.0 mmol) of hydrazine hydrate was stirred for 3 h at room temperature. The mixture was diluted with 20 mL of water and extracted with ethyl acetate (3×10 mL), the combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure, and the oily residue was crystallized from benzene–petroleum ether–acetone (30:10:1). Yield 68 mg (44%), pale pink crystals, mp 147–148°C. IR spectrum,  $\nu$ , cm<sup>-1</sup>: 3030 m (NH), 2908 w (C–H<sub>aliph</sub>), 1681 s (C=O), 1660 m (C=N), 1591 s (C=C<sub>arom</sub>), 1223 s (C–O), 1083 s (C–O), 694 s ( $\delta$ C–H<sub>arom</sub>). <sup>1</sup>H NMR spectrum,  $\delta$ , ppm: 1.15 t (3H, CH<sub>3</sub>,  $J = 7.1$  Hz), 1.96 s (3H, CH<sub>3</sub>), 2.11 s (3H, CH<sub>3</sub>), 2.47 s (3H, CH<sub>3</sub>), 4.00–4.16 m (2H, CH<sub>2</sub>O), 5.55 s (1H, CH), 7.20–7.40 m (5H, Ph),

11.53 br.s (1H, NH), 12.05 br.s (1H, NH). <sup>13</sup>C NMR spectrum,  $\delta_C$ , ppm: 14.1 (CH<sub>3</sub>), 18.6 (CH<sub>3</sub>), 19.4 (CH<sub>3</sub>), 25.2 (CH<sub>3</sub>), 54.1 (CH), 60.9 (CH<sub>2</sub>O), 103.8 (C<sup>5</sup>); 127.0 (CH), 129.1 (CH), 129.2 (CH), 141.5 (Ph); 142.9 (Me<sub>2</sub>C=), 149.1 (C<sup>6</sup>), 159.7 (C<sup>2</sup>), 164.6 (5-C=O). Found, %: C 64.91; H 7.17; N 17.78. C<sub>17</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>. Calculated, %: C 64.95; H 7.05; N 17.82.

## FUNDING

This study was performed under financial support by the Ministry of Science and Higher Education of the Russian Federation in the framework of the base part of state assignment in the field of research activity (project no. 4.6764.2017/BCh).

## CONFLICT OF INTERESTS

The authors declare the absence of conflict of interests.

## REFERENCES

1. Biginelli, P., *Gazz. Chim. Ital.*, 1893, vol. 23, p. 360.
2. Vdovina, S.V. and Mamedov, V.A., *Russ. Chem. Rev.*, 2008, vol. 77, p. 1017. doi 10.1070/RC2008v077n12ABEH003894
3. Wan, J.-P. and Liu, Y., *Synthesis*, 2010, no. 23, p. 3943. doi 10.1055/s-0030-1258290
4. Sandhu, S.S. and Sandhu, J.S., *Arkivoc*, 2012, part (i), p. 66. doi 10.3998/ark.5550190.0013.103
5. Alvim, H.G., Lima, T.B., de Oliveira, A.L., de Oliveira, H.C., Silva, F.M., Gozzo, F.C., and Neto, B.A., *J. Org. Chem.*, 2014, vol. 79, p. 3383. doi 10.1021/jo5001498
6. Patil, R., Chavan, J., and Beldar, A., *World J. Pharm. Pharm. Sci.*, 2016, vol. 5, p. 419. doi 10.20959/wjpps201611-7959
7. Nilsson, B.L. and Overman, L.E., *J. Org. Chem.*, 2006, vol. 71, p. 7706. doi 10.1021/jo061199m
8. Wagman, A.S., Boyce, R.S., Brown, S.P., Fang, E., Goff, D., Jansen, J.M., Le, V.P., Levine, B.H., Ng, S.C., Ni, Z.-J., Nuss, J.M., Pfister, K.B., Ramurthy, S., Renhowe, P.A., Ring, D.B., Shu, W., Subramanian, S., Zhou, X.A., Shafer, C.M., Harrison, S.D., Johnson, K.W., and Bussiere, D.E., *J. Med. Chem.*, 2017, vol. 60, p. 8482. doi 10.1021/acs.jmedchem.7b00922
9. Ibrahim, D.A. and El-Metwally, A.M., *Eur. J. Med. Chem.*, 2010, vol. 45, p. 1158. doi 10.1016/j.ejmech.2009.12.026
10. El-Mahdy, K.M. and El-Kazak, A.M., *Heterocycles*, 2013, vol. 87, p. 41. doi 10.3987/COM-13-12663

11. Shiryaev, A.K., Kolesnikova, N.G., Kuznetsova, N.M., and Lashmanova, E.A., *Chem. Heterocycl. Compd.*, 2014, vol. 49, p. 1681. doi 10.1007/s10593-014-1420-8
12. Lashmanova, E.A. and Shiryaev, A.K., *Chem. Heterocycl. Compd.*, 2015, vol. 51, p. 377. doi 10.1007/s10593-015-1710-9
13. Metwally, N.H. and El-Doseky, I.A., *Synth. Commun.*, 2015, vol. 45, p. 2683. doi 10.1080/00397911.2015.1100312
14. Lashmanova, E.A., Kirdyashkina, A.I., Slepukhin, P.A., and Shiryaev, A.K., *Tetrahedron Lett.*, 2018, vol. 59, p. 1099. doi 10.1016/j.tetlet.2018.02.014
15. Shiryaev, A.K., Baranovskaya, N.S., and Eremin, M.S., *Chem. Heterocycl. Compd.*, 2013, vol. 48, p. 1550. doi 10.1007/s10593-013-1172-x
16. Alikarami, M. and Moradi, R., *Lett. Org. Chem.*, 2015, vol. 12, p. 560. doi 10.2174/1570178612666150528212749